Literature DB >> 23764889

PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinoma.

Rachel L G M Blom1, Inge R Steenbakkers, Guido Lammering, Roy F A Vliegen, Eric J Belgers, Charlotte de Jonge, Wendy M J Schreurs, Marius Nap, Meindert N Sosef.   

Abstract

PURPOSE: Neoadjuvant chemoradiotherapy is increasingly used in oesophageal cancer patients. In general, small tumours are associated with a survival benefit compared to large tumours. Little is known, however, about the relationship between initial tumour volume and response to chemoradiotherapy. Therefore, the aim of this study was to determine whether the pretherapy metabolic tumour volume (MTV) on diagnostic PET/CT in oesophageal cancer patients is correlated with response to chemoradiotherapy in the resection specimen.
METHODS: A consecutive series of patients underwent diagnostic PET/CT scanning prior to chemoradiotherapy and oesophagectomy. MTVs were determined on PET/CT and an automated tumour contour was generated using specified standard uptake value thresholds. Response to chemoradiotherapy was determined in the resection specimen according to the scoring system developed by Mandard et al. Patients were divided into different groups according to response to chemoradiotherapy.
RESULTS: Between January 2008 and May 2011 a total of 115 patients underwent an oesophagectomy. The MTV determined on diagnostic PET/CT scans was available in 79 patients. Of these 79 patients, 30 (38 %) showed no residual tumour cells at the location of the primary tumour. Three of these patients presented with residual tumour cells in the lymph nodes; 27 patients (34 %) had a complete pathological response. There was a trend towards a better response in patients with a smaller MTV (p = 0.084).
CONCLUSION: This study demonstrated a trend towards a correlation between response to chemoradiotherapy in oesophageal cancer patients and smaller MTVs as determined on diagnostic PET/CT prior to neoadjuvant chemoradiotherapy. However, tumour volumes overlapped between groups, indicating the need for multifactorial parameters as predictors. In addition, a complete local tumour response may be accompanied by residual disease in the regional lymph nodes.

Entities:  

Mesh:

Year:  2013        PMID: 23764889     DOI: 10.1007/s00259-013-2468-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  25 in total

1.  Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters.

Authors:  Seung Hwan Moon; Joon Young Choi; Hwan Joo Lee; Young-Ik Son; Chung-Hwan Baek; Yong Chan Ahn; Keunchil Park; Kyung-Han Lee; Byung-Tae Kim
Journal:  Head Neck       Date:  2012-02-06       Impact factor: 3.147

2.  Post-treatment endoscopic biopsy for prediction of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer.

Authors:  Jung-Jyh Hung; Wen-Juei Jeng; Jung-Sen Liu
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

3.  Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET.

Authors:  Marinke Westerterp; Jikke M T Omloo; Gerrit W Sloof; Maarten C C M Hulshof; Otto S Hoekstra; Hans Crezee; Ronald Boellaard; Walter L Vervenne; Fiebo J W ten Kate; Jan J B van Lanschot
Journal:  Int J Hyperthermia       Date:  2006-03       Impact factor: 3.914

4.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.

Authors:  Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

5.  Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.

Authors:  Johannes B Roedl; Mukesh G Harisinghani; Rivka R Colen; Alan J Fischman; Michael A Blake; Douglas J Mathisen; Peter R Mueller
Journal:  Ann Thorac Surg       Date:  2008-10       Impact factor: 4.330

6.  Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.

Authors:  Mark van Heijl; Jikke M Omloo; Mark I van Berge Henegouwen; Otto S Hoekstra; Ronald Boellaard; Patrick M Bossuyt; Olivier R Busch; Hugo W Tilanus; Maarten C Hulshof; Ate van der Gaast; Grard A Nieuwenhuijzen; Han J Bonenkamp; John Th Plukker; Miguel A Cuesta; Fiebo J Ten Kate; Jan Pruim; Herman van Dekken; Jacques J Bergman; Gerrit W Sloof; J Jan van Lanschot
Journal:  Ann Surg       Date:  2011-01       Impact factor: 12.969

7.  Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.

Authors:  Min P Kim; Arlene M Correa; Jared Lee; David C Rice; Jack A Roth; Reza J Mehran; Garrett L Walsh; Jaffer A Ajani; Dipen M Maru; Joe Y Chang; Edith M Marom; Homer A Macapinlac; Jeff H Lee; Ara A Vaporciyan; Thomas Rice; Stephen G Swisher; Wayne L Hofstetter
Journal:  Ann Thorac Surg       Date:  2010-09       Impact factor: 4.330

8.  18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.

Authors:  Remy Lim; Anne Eaton; Nancy Y Lee; Jeremy Setton; Nisha Ohri; Shyam Rao; Richard Wong; Matthew Fury; Heiko Schöder
Journal:  J Nucl Med       Date:  2012-08-14       Impact factor: 10.057

9.  Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.

Authors:  Johannes B Roedl; Rivka R Colen; Nagaraj S Holalkere; Alan J Fischman; Noah C Choi; Michael A Blake
Journal:  Radiother Oncol       Date:  2008-08-11       Impact factor: 6.280

10.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.

Authors:  Jan B F Hulscher; Johanna W van Sandick; Angela G E M de Boer; Bas P L Wijnhoven; Jan G P Tijssen; Paul Fockens; Peep F M Stalmeier; Fiebo J W ten Kate; Herman van Dekken; Huug Obertop; Hugo W Tilanus; J Jan B van Lanschot
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

View more
  15 in total

1.  A study about different findings of PET-CT between neoadjuvant and non-neoadjuvant therapy: SUVmax is not a reliable predictor of lymphatic involvement after neoadjuvant therapy for esophageal cancer.

Authors:  Jae Kil Park; Jae Jun Kim; Seok Whan Moon
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

2.  Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer.

Authors:  Dietmar Tamandl; Richard M Gore; Barbara Fueger; Patrick Kinsperger; Michael Hejna; Matthias Paireder; Alexander Haug; Sebastian F Schoppmann; Ahmed Ba-Ssalamah
Journal:  Eur Radiol       Date:  2015-06-05       Impact factor: 5.315

Review 3.  Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma.

Authors:  Kazuto Harada; Dilsa Mizrak Kaya; Anthony Lopez; Hideo Baba; Jaffer A Ajani
Journal:  Ann Transl Med       Date:  2018-02

4.  Intratumoral Metabolic Heterogeneity and Other Quantitative 18F-FDG PET/CT Parameters for Prognosis Prediction in Esophageal Cancer.

Authors:  Akilan Gopal; Yin Xi; Rathan M Subramaniam; Daniella F Pinho
Journal:  Radiol Imaging Cancer       Date:  2020-12-18

5.  Pretreatment 18F-FDG PET/CT-Derived Parameters in Predicting Clinical Outcomes of Locally Advanced Upper Third Esophageal Squamous Cell Carcinoma After Definitive Chemoradiation Therapy.

Authors:  Le Ngoc Ha; Nguyen Dinh Chau; Bui Quang Bieu; Mai Hong Son
Journal:  Nucl Med Mol Imaging       Date:  2022-05-10

6.  Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma.

Authors:  Charles Lemarignier; Frédéric Di Fiore; Charline Marre; Sébastien Hapdey; Romain Modzelewski; Pierrick Gouel; Pierre Michel; Bernard Dubray; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-19       Impact factor: 9.236

7.  The emerging field of radiomics in esophageal cancer: current evidence and future potential.

Authors:  Peter S N van Rossum; Cai Xu; David V Fried; Lucas Goense; Laurence E Court; Steven H Lin
Journal:  Transl Cancer Res       Date:  2016-08       Impact factor: 1.241

8.  Association between the inflammatory biomarker, C-reactive protein, and the response to radiochemotherapy in patients with esophageal cancer.

Authors:  Harun Badakhshi; David Kaul; Kuai-LE Zhao
Journal:  Mol Clin Oncol       Date:  2016-01-28

9.  Prognostic value of SUR in patients with trimodality treatment of locally advanced esophageal carcinoma.

Authors:  Rebecca Bütof; Frank Hofheinz; Klaus Zöphel; Julia Schmollack; Christina Jentsch; Sebastian Zschaeck; Jörg Kotzerke; Jörg van den Hoff; Michael Baumann
Journal:  J Nucl Med       Date:  2018-08-30       Impact factor: 10.057

10.  Usefulness of positron emission tomography-computed tomography in pre-operative evaluation of intra-thoracic esophageal cancer.

Authors:  Jae Jun Kim; Jae Kil Park; Seok Whan Moon
Journal:  Thorac Cancer       Date:  2015-03-06       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.